281 related articles for article (PubMed ID: 18766323)
1. Molecular mechanisms underlying the onset of degenerative aortic valve disease.
Hakuno D; Kimura N; Yoshioka M; Fukuda K
J Mol Med (Berl); 2009 Jan; 87(1):17-24. PubMed ID: 18766323
[TBL] [Abstract][Full Text] [Related]
2. [Role of anti-angiogenic factor chondromodulin-I for maintaining cardiac valvular function].
Hakuno D; Fukuda K
Clin Calcium; 2007 Mar; 17(3):361-72. PubMed ID: 17339740
[TBL] [Abstract][Full Text] [Related]
3. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis.
Yoshioka M; Yuasa S; Matsumura K; Kimura K; Shiomi T; Kimura N; Shukunami C; Okada Y; Mukai M; Shin H; Yozu R; Sata M; Ogawa S; Hiraki Y; Fukuda K
Nat Med; 2006 Oct; 12(10):1151-9. PubMed ID: 16980969
[TBL] [Abstract][Full Text] [Related]
4. An epigenetic regulatory loop controls pro-osteogenic activation by TGF-β1 or bone morphogenetic protein 2 in human aortic valve interstitial cells.
Song R; Fullerton DA; Ao L; Zhao KS; Meng X
J Biol Chem; 2017 May; 292(21):8657-8666. PubMed ID: 28377507
[TBL] [Abstract][Full Text] [Related]
5. TGF-β mediates early angiogenesis and latent fibrosis in an Emilin1-deficient mouse model of aortic valve disease.
Munjal C; Opoka AM; Osinska H; James JF; Bressan GM; Hinton RB
Dis Model Mech; 2014 Aug; 7(8):987-96. PubMed ID: 25056700
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis.
Soini Y; Salo T; Satta J
Hum Pathol; 2003 Aug; 34(8):756-63. PubMed ID: 14506635
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory role of Notch1 in calcific aortic valve disease.
Acharya A; Hans CP; Koenig SN; Nichols HA; Galindo CL; Garner HR; Merrill WH; Hinton RB; Garg V
PLoS One; 2011; 6(11):e27743. PubMed ID: 22110751
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure.
Shuvy M; Abedat S; Beeri R; Valitsky M; Daher S; Kott-Gutkowski M; Gal-Moscovici A; Sosna J; Rajamannan NM; Lotan C
Am J Physiol Heart Circ Physiol; 2011 May; 300(5):H1829-40. PubMed ID: 21335463
[TBL] [Abstract][Full Text] [Related]
9. The lipid theory in the pathogenesis of calcific aortic stenosis.
Parisi V; Leosco D; Ferro G; Bevilacqua A; Pagano G; de Lucia C; Perrone Filardi P; Caruso A; Rengo G; Ferrara N
Nutr Metab Cardiovasc Dis; 2015 Jun; 25(6):519-25. PubMed ID: 25816732
[TBL] [Abstract][Full Text] [Related]
10. Release of leukotriene B4, transforming growth factor-beta1 and microparticles in relation to aortic valve calcification.
Kochtebane N; Passefort S; Choqueux C; Ainoun F; Achour L; Michel JB; Bäck M; Jacob MP
J Heart Valve Dis; 2013 Nov; 22(6):782-8. PubMed ID: 24597398
[TBL] [Abstract][Full Text] [Related]
11. Conserved transcriptional regulatory mechanisms in aortic valve development and disease.
Wirrig EE; Yutzey KE
Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):737-41. PubMed ID: 24665126
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells.
Mahler GJ; Farrar EJ; Butcher JT
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):121-30. PubMed ID: 23104848
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of simvastatin treatment of valvular interstitial cells varies with the extracellular environment.
Monzack EL; Gu X; Masters KS
Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):246-53. PubMed ID: 19023089
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-β1 promotes fibrosis but attenuates calcification of valvular tissue applied as a three-dimensional calcific aortic valve disease model.
Jenke A; Kistner J; Saradar S; Chekhoeva A; Yazdanyar M; Bergmann AK; Rötepohl MV; Lichtenberg A; Akhyari P
Am J Physiol Heart Circ Physiol; 2020 Nov; 319(5):H1123-H1141. PubMed ID: 32986963
[TBL] [Abstract][Full Text] [Related]
15. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation.
Caira FC; Stock SR; Gleason TG; McGee EC; Huang J; Bonow RO; Spelsberg TC; McCarthy PM; Rahimtoola SH; Rajamannan NM
J Am Coll Cardiol; 2006 Apr; 47(8):1707-12. PubMed ID: 16631011
[TBL] [Abstract][Full Text] [Related]
16. VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins.
Anger T; Pohle FK; Kandler L; Barthel T; Ensminger SM; Fischlein T; Weyand M; Stumpf C; Daniel WG; Garlichs CD
Exp Mol Pathol; 2007 Dec; 83(3):435-42. PubMed ID: 17490641
[TBL] [Abstract][Full Text] [Related]
17. Atherosclerotic inflammation triggers osteogenic bone transformation in calcified and stenotic human aortic valves: still a matter of debate.
Anger T; Carson W; Weyand M; Daniel WG; Hoeher M; Garlichs CD
Exp Mol Pathol; 2009 Feb; 86(1):10-7. PubMed ID: 19084515
[TBL] [Abstract][Full Text] [Related]
18. Do statins slow the process of calcification of aortic tissue valves?
Gilmanov D; Bevilacqua S; Mazzone A; Glauber M
Interact Cardiovasc Thorac Surg; 2010 Sep; 11(3):297-301. PubMed ID: 20570976
[TBL] [Abstract][Full Text] [Related]
19. Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement.
Yeghiazaryan K; Skowasch D; Bauriedel G; Schild H; Golubnitschaja O
Amino Acids; 2007 Jan; 32(1):109-14. PubMed ID: 16874466
[TBL] [Abstract][Full Text] [Related]
20. [The role of angiogenetic factors in the pathogenesis and the progression of cardiac valve disease].
Kusumoto D; Fukuda K
Clin Calcium; 2013 Apr; 23(4):481-8. PubMed ID: 23545737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
